47 completed, 4 terminated, 2 unknown, 1 withdrawn. 16 Phase 4, 12 Phase 1, 10 Phase 3, 6 Phase 2, 3 Not applicable.
Follow fesoterodine: new trials by email Literature Review of fesoterodine trials Research Report on fesoterodine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics Oxybutynin, Solifenacin, Tolterodine, Trospium, or Fesoterodine - Urinary Incontinence, Urgency Urinary | Phase 4 | Completed | Brigham and Women's Hospital | 20 | 2019-10-30 | 2022-11-15 |
| Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania mirabegron, solifenacin, darifenacin - Overactive Bladder (OAB) | Completed | Astellas Pharma Singapore Pte. Ltd. | 5589 | 2018-07-20 | 2024-10-16 | |
| A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China mirabegron, solifenacin, darifenacin - Overactive Bladder (OAB) | Completed | Astellas Pharma Singapore Pte. Ltd. | 805 | 2018-07-19 | 2020-04-22 | |
| Fesoterodine on Urgency Episodes in Parkinson's Disease Population Fesoterodine, Placebo - Urinary Bladder, Overactive, Parkinson Disease | Phase 4 | Terminated | Sir Mortimer B. Davis - Jewish General Hospital | 5 | 2016-09-01 | 2019-09-26 |
| A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment fesoterodine 4mg, Oxybutynin, placebo - Overactive Bladder, Mild Cognitive Impairment | Phase 2 | Completed | University of Alberta | 47 | 2016-08-01 | 2020-02-19 |
| Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI) Fesoterodine - Autonomic Dysreflexia | Phase 2 | Completed | University of British Columbia | 15 | 2016-02-25 | 2019-09-09 |
| Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children. Fesoterodine - Overactive Bladder | Phase 3 | Completed | Stéphane Bolduc | 26 | 2015-10-01 | 2019-07-30 |
| Fall Prevention in Older Adults With OAB Fesoterodine - Overactive Bladder | Phase 4 | Completed | University of Pennsylvania | 74 | 2015-07-25 | 2023-05-06 |
| Comparison Between Desmopressin and Fesoterodine for Treatment of Night Time Voiding in Women Aged 65 and Older Desmopressin, Fesoterodine - Nocturia | Phase 2 / Phase 3 | Terminated | Mount Sinai Hospital, Canada | 4 | 2015-07-01 | 2016-11-15 |
| A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB) mirabegron, antimuscarinic medication - Urinary Bladder Overactive, Overactive Bladder | Completed | Astellas Scientific & Medical Affairs, Inc. | 1524 | 2015-01-05 | 2024-10-16 | |
| Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children Fesoterodine, Oxybutynin XL - Overactive Bladder | Phase 3 | Completed | Stéphane Bolduc | 62 | 2014-12-01 | 2019-07-30 |
| Study to Estimate the Relative Bioavailability Compared to Commercial Extended-release Tablet Formulation and the Effects of Food Or Sprinkling on Applesauce for Fesoterodine Sustained-release Beads-in-capsule Formulations in Healthy Adult Volunteers Fesoterodine ER (fasted), Fesoterodine SR3 (fasted), Fesoterodine SR3 (fed) - Healthy | Phase 1 | Completed | Pfizer | 24 | 2014-07-01 | 2015-01-15 |
| Drug Use Investigation for Toviaz Fesoterodine (Toviaz) - Overactive Bladder (OAB) | Completed | Pfizer | 2521 | 2013-10-01 | 2021-06-11 | |
| Understanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly (URGE) Fesoterodine Fumarate - Urge Urinary Incontinence | Phase 3 | Completed | University of North Carolina, Chapel Hill | 61 | 2012-09-01 | 2020-03-18 |
| Trial of Percutaneous Tibial Nerve Stimulation (PTNS) Versus PTNS and Fesoterodine Fumarate Fesoterodine fumarate, Placebo, Percutaneous Tibial Nerve Stimulation (PTNS) - Overactive Bladder | Phase 4 | Terminated | Mayo Clinic | 4 | 2012-06-01 | 2014-02-05 |
| A Study To Estimate The Effects Of Food On Drug Fesoterodine Fumarate And The Pharmacokinetics Of 5-Hydroxymethyl Tolterodine (5-HMT) In Healthy Volunteers fesoterodine fumarate - Urinary Bladder, Overactive | Phase 1 | Completed | Pfizer | 24 | 2012-05-01 | 2016-08-19 |
| Solifenacin Succinate Versus Fesoterodine A Comparison Trial for Urgency Symptoms solifenacin succinate, fesoterodine - Urinary Bladder, Overactive | Not applicable | Unknown | Rambam Health Care Campus | 60 | 2012-05-01 | 2012-05-16 |
| Premarin Versus Toviaz for Treatment of Overactive Bladder Toviaz, Premarin, Placebo cream - Overactive Bladder | Phase 4 | Unknown | The Cleveland Clinic | 90 | 2012-04-01 | 2017-04-20 |
| A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy Fesoterodine, Placebo oral tablet - Prostate Adenocarcinoma | Phase 4 | Completed | Abramson Cancer Center at Penn Medicine | 3 | 2012-01-01 | 2020-04-28 |
| A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine. Fesoterodine 8 mg, Placebo - Urinary Bladder, Overactive | Phase 4 | Completed | Pfizer | 990 | 2011-05-01 | 2018-12-04 |
Showing 20 of 54. Sign in to see all of them.
Urinary Bladder, Overactive (37) · Urinary Incontinence, Urge (5) · Urinary Incontinence (3) · Autonomic Dysreflexia (1) · Cognitive Dysfunction (1) · Nocturia (1) · Parkinson Disease (1) · Spinal Cord Injuries (1) · Stroke (1) · Urinary Bladder Diseases (1) · Urinary Bladder Neck Obstruction (1) · Urinary Incontinence, Stress (1) · Urologic Diseases (1)
Pfizer (31) · Astellas Pharma Singapore Pte. Ltd. (2) · Stéphane Bolduc (2) · University of Pennsylvania (2) · Abramson Cancer Center at Penn Medicine (1) · Astellas Scientific & Medical Affairs, Inc. (1) · Brigham and Women's Hospital (1) · LG Life Sciences (1) · Mayo Clinic (1) · Mount Sinai Hospital, Canada (1) · Rambam Health Care Campus (1) · Saint Thomas Health (1) · Samsung Medical Center (1) · Sir Mortimer B. Davis - Jewish General Hospital (1) · The Cleveland Clinic (1)
United States (28) · Canada (11) · South Korea (11) · Germany (7) · Poland (6) · Slovakia (6) · Sweden (6) · Belgium (5) · Singapore (5) · Ukraine (5) · Colombia (4) · Czechia (4) · Denmark (4) · Greece (4) · Hungary (4)
Adrian S Wagg, MD (1) · Alexandriah Alas, MD (1) · Alexis Te, MD (1) · Andrei Krassioukov, MD,PhD,FRCPC (1) · Anna Padoa, MD (1) · Barry K Jarnagin, MD (1) · David Lee, MD (1) · David Shveiky, MD (1) · Eric Hurtado, MD (1) · H. Henry Lai, M.D. (1) · Haim Krissi, MD (1) · Harold P Drutz, MD (1) · Jeanette S. Brown, MD (1)
PMID 37160401, PMID 35881009, PMID 19348029, PMID 21428726, PMID 23171069, PMID 23460503, PMID 23973522, PMID 24258099, PMID 24552358, PMID 24898471, PMID 29324595, PMID 29777865, PMID 30467135, PMID 31222714, PMID 34807883, PMID 36892754, PMID 37148497, PMID 38402104, PMID 38430402
2014 (1), R03AG042335 (1)